We’re developing targeted therapies to lower LDL-cholesterol for patients not adequately treated with current lipid-modifying therapies.

Learn More


Esperion is a late-stage pharmaceutical company focused on developing and commercializing non-statin, convenient, complementary, consistent, once-daily, oral, LDL-C lowering therapies for the treatment of patients with hypercholesterolemia.

learn more


New AHA/ACC Blood Cholesterol Management Guidelines

New Blood Cholesterol Management Guidelines. This weekend, the American College of Cardiology (ACC) and the American Heart Association (AHA) published an… more

Posted by mlowe@esperion.com

U.S. CDC Highlights High Unmet Cardiovascular Need

A new report published by the U.S. Centers for Disease Control and Prevention (CDC) sheds light on an issue that… more

Posted by Andrew Jillions

Investor Day and July Meetings Recap

Hi, I’m Alex Schwartz and I recently joined Esperion as Head of Investor Relations.  Prior to joining Esperion, I was… more

Posted by mlowe@esperion.com